Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-HAE phase 3 trial of ADX-324 for prevention of hereditary angioedema attacks
MOH_2026-03-01_015693Phase 3Recruiting
- Sponsor
- ADARx Pharmaceuticals
- Start
- Feb 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing ADX-324 300 mg then placebo, ADX-324 240 mg twice and Placebo twice (3 arms). Primary endpoint: Efficacy of ADX-324 in prevention of hereditary angioedema attacks. Started Feb 2026; status: recruiting.
02
Drugs
onvuzosiran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2026-03-01_015693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-01_015693.